Skip to main content

Table 2 Changes of parameters of interest pre- and post-medical treatment

From: Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats

Variables

Sham

Control

Low-dose

High-dose

Pre-medical treatment (8 weeks of model production, n = 5 each group)

Body weight (g)

254.8 ± 6.6*

286.6 ± 7.0

290.3 ± 8.7

288.5 ± 10.4

TG (mmol/L)

1.15 ± 0.17*

1.79 ± 0.33

1.78 ± 0.32

1.76 ± 0.43

TC (mmol/L)

3.96 ± 0.26*

4.97 ± 0.34

4.96 ± 0.37

4.95 ± 0.45

LDL-C (mmol/L)

2.12 ± 0.24*

2.85 ± 0.31

2.91 ± 0.57

2.89 ± 0.44

HDL-C (mmol/L)

1.07 ± 0.12

1.11 ± 0.04

1.12 ± 0.04

1.10 ± 0.05

FBG (mmol/L)

4.12 ± 0.08*

4.49 ± 0.11

4.51 ± 0.12

4.50 ± 0.08

NO (umol/L)

12.67 ± 1.37*

9.65 ± 1.05

9.26 ± 1.08

9.44 ± 1.02

CRP (mg/L)

2.15 ± 0.42*

6.37 ± 0.55

6.52 ± 0.73

6.46 ± 0.52

MDA (nmol/L)

0.90 ± 0.06*

2.46 ± 0.18

2.57 ± 0.12

2.52 ± 0.19

ADMA (ng/mL)

43.37 ± 6.65*

60.68 ± 10.17

62.22 ± 8.17

62.30 ± 8.22

Post-medical treatment (4 weeks of medical treatment, n = 10 each group)

Body weight (g)

277.3 ± 8.2*

301.2 ± 7.4

299.6 ± 10.3

300.6 ± 10.5

TG (mmol/L)

1.17 ± 0.22*

1.83 ± 0.42

1.67 ± 0.37

1.50 ± 0.29#

TC (mmol/L)

3.98 ± 0.33*

5.00 ± 0.62

4.81 ± 0.56

4.56 ± 0.36#

LDL-C (mmol/L)

2.13 ± 0.23*

2.87 ± 0.36

2.64 ± 0.52

2.43 ± 0.35#

HDL-C (mmol/L)

1.07 ± 0.14

1.10 ± 0.05

1.12 ± 0.03

1.10 ± 0.03

FBG (mmol/L)

4.14 ± 0.07*

4.56 ± 0.13

4.46 ± 0.15

4.41 ± 0.13

NO (umol/L)

12.88 ± 1.56*

9.03 ± 0.68

10.07 ± 0.64

10.85 ± 0.57#

CRP (mg/L)

2.13 ± 0.39*

6.43 ± 0.42

5.87 ± 0.16

5.35 ± 0.66#

MDA (nmol/L)

0.93 ± 0.07*

2.52 ± 0.15

2.29 ± 0.09

2.05 ± 0.07#

ADMA (ng/mL)

44.64 ± 7.08*

62.33 ± 10.08

58.75 ± 8.07

54.46 ± 9.15#

ALT (U/L)

21.43 ± 3.24

26.55 ± 5.21

24.47 ± 6.08

22.39 ± 3.76

AST (U/L)

24.36 ± 6.77

22.55 ± 4.09

21.56 ± 3.35

23.30 ± 6.12

CK (U/L)

18.24 ± 2.23

21.30 ± 2.08

20.07 ± 3.35

20.35 ± 2.56

  1. Denote: *P < 0.05 versus other groups, #P < 0.05 versus control group.